News Category: News and Insights

The Life Science business of Merck KGaA, Darmstadt, Germany Acquires HUB Organoids Holding B.V., Expands Next-Gen Biology Portfolio

Reinforces company’s commitment to differentiated solutions that enable faster and more effective drug development HUB’s organoid offering complements company’s cell culture portfolio...

The Life Science business of Merck KGaA, Darmstadt, Germany, to Acquire HUB Organoids Holding B.V., Advancing Next Generation Biology Portfolio

HUB internationally recognized pioneer in organoid development Acquisition expands Merck’s 2D and 3D cell culture portfolio Organoids part of fastest growing cell...

HUB Organoids B.V. Awarded Frost & Sullivan’s 2024 Technology Innovation Leadership Award for Transforming Drug Development with Highly Advanced Organoid Technology

HUB Organoids B.V. revolutionizes preclinical and clinical drug development through its cutting-edge organoid technology, enhancing its accuracy and efficiency. San Antonio, TX...

HUB Organoids Launches IntegriGut Screen: A Breakthrough Service Offering for Inflammatory Bowel Disease (IBD) Drug Discovery and Development

Utrecht, Netherlands – 25th Jan 2024 – HUB Organoids (HUB), a global leader and sole proprietor of patient-derived organoid technology for drug...

Tumors in Space Investigates Microgravity’s Impact on Cancer Using Patient-Derived HUB Organoids

Utrecht, November 30, 2023 – HUB Organoids B.V. participates in the second Tumors in Space European Space Agency parabolic flight which investigates...

HUB Organoids Announces New Corporate Strategy and Completes Transition from Foundation to Private Company

[Utrecht, July 18 2023] — HUB Organoids (HUB), the global leader in the field of patient-derived organoids, is excited to announce a...

HUB Organoids extends partnership with Molecular Devices to advance automated intestinal organoid screening technology

SAN JOSE, Calif., and UTRECHT, Netherlands, Feb. 13, 2023 – Molecular Devices, LLC., a leading provider of high-performance life science solutions, and...

HUB Organoids take their first parabolic flight!

FDA Modernization Act 2.0: We welcome the dawn of an organoid era

Imagine Reducing the Time to Identify a Drug

Patients with mutated KRAS (Kirsten rat sarcoma virus) gene account for around 30-50% of the population with colorectal cancer (CRC) and do...